NCT02577003View on ClinicalTrials.gov

Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)

PHASE3CompletedINTERVENTIONAL

Enrollment

143

Participants

Timeline

Start Date

November 9, 2015

Primary Completion Date

November 25, 2016

Study Completion Date

November 25, 2016

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Ipragliflozin

50 mg tablet administered orally

DRUG

Placebo

Placebo to ipragliflozin tablet administered orally

DRUG

Sitagliptin

Background medication; 50 mg tablet administered orally

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02577003 - Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843) | Biotech Hunter | Biotech Hunter